[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-446311-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-446311-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-siglec9-in-immunosuppression-and-prognosis-in-cervical-cancer","The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer","","Objective: This study investigates the role of Sialic acid-binding Immunoglobulin-Like Lectin-9 (SIGLEC9), a novel immune checkpoint, in cervical cancer and its interaction with immune cells in the tumor microenvironment. Methods: SIGLEC9 expression was assessed using TNM plot, TCGA, and Human Protein Atlas; immune infiltration was analyzed with TCGA and TISIDB; single-cell and interaction datasets were integrated, and multiple lab assays validated findings. Results: SIGLEC9 was upregulated and correlated with poor prognosis, especially via SIGLEC9+ tumor-associated macrophages and T-cells. Conclusion: SIGLEC9 supports progression and prognosis through TAMs and T-cells and may be a target for immunotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-siglec9-in-immunosuppression-and-prognosis-in-cervical-cancer/446311/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-siglec9-in-immunosuppression-and-prognosis-in-cervical-cancer/446311.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the study on SIGLEC9?","Question",{"text":63,"@type":64},"To investigate how SIGLEC9, an immune checkpoint, contributes to immunosuppression in cervical cancer and how it affects prognosis through interactions with immune cells in the tumor microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was SIGLEC9 expression and immune infiltration analyzed?",{"text":68,"@type":64},"SIGLEC9 expression in cervical cancer was analyzed using the TNM plot, TCGA, and Human Protein Atlas, and its relationship with immune cell infiltration was explored using TCGA and TISIDB.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about SIGLEC9 and prognosis?",{"text":72,"@type":64},"SIGLEC9 was significantly upregulated in cervical cancer, and higher expression was associated with poor prognosis, including reduced overall survival linked to elevated SIGLEC9+ tumor-associated macrophages.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},446311,1791291861,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Clinics 81 (2026) 100849  \nContents lists available at ScienceDirect  \nClinics  \njournal [homepage:](homepage: www.elsevier.com/locate/clinsp)[ www.elsevier.com/locate/clinsp](homepage: www.elsevier.com/locate/clinsp)  \n| Original articles\u003Cbr>The role of SIGLEC9 cervical cancer | in immunosuppression and |  |  | prognosis in | |\n| --- | --- | --- | --- | --- | --- |\n| Bihui Wang a,b , Yuejie Zhu c, Zhenyu Rud, Yulian Zhang a,b , Mingkai Yue , Pingfen Li f,\u003Cbr>Manli Zhang c , Jianbing Ding g , Zhifang Chena,b,* \u003Cbr>a Department of Gynecology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China\u003Cbr>b State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China\u003Cbr>c Center for Reproductive Medicine, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China d Department of Gastroenterology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China e School of Life Science and Technology, Southeast University, Nanjing, China\u003Cbr>f Department of Reproductive Medicine, The First Affiliated Hospital of Xi’an Jiao Tong University, Shanxi, Xi’an, China g Department of Immunology, College of Basic Medicine of Xinjiang Medical University, Urumqi, China |  |  |  |  |  |\n| A R T I C L E I N F O |  |  | A B S T R A C T |  |  |\n| Edited by: Jose´ Maria Soares Junior. |  |  | Objective: This study investigates the role of Sialic acid-binding Immunoglobulin-Like Lectin-9 (SIGLEC9), a novel immune checkpoint, in Cervical Cancer (CC) and its interaction with immune cells in the tumor microenvironment.\u003Cbr>Methods: SIGLEC9 expression in CC was analyzed using the TNM plot, TCGA, and Human Protein Atlas databases, alongside its correlation with tumor stage. The relationship between SIGLEC9 expression and immune cell infiltration was explored using TCGA and TISIDB databases. Single-cell analysis focused on SIGLEC9 in macrophages. Protein interactions were assessed through the String, IntAct, BioGRID, and Mentha databases. MUC1 expression was validated via GEO and GEPIA databases. Immunohistochemical staining, western blot, immunofluorescence, and flow cytometry were used for verification. The prognostic significance of SIGLEC9 and SIGLEC9+ Tumor-Associated Macrophages (TAMs) was evaluated.\u003Cbr>Results: SIGLEC9 was found to be significantly upregulated in CC, with higher levels correlating with poor prognosis. It was expressed in macrophages and T-cells, and elevated SIGLEC9+ TAMs were linked to reduced overall survival.\u003Cbr>Conclusion: SIGLEC9 plays a crucial role in the progression and prognosis of cervical cancer through its interaction with TAMs and T-cells. These findings highlight SIGLEC9 as a potential target for new immunotherapies in CC. |  |  |\n| Keywords:\u003Cbr>Cervical Cancer (CC)\u003Cbr>Sialic Acid-Binding Immunoglobulin-Like Lectin-9 (SIGLEC9)\u003Cbr>Mucin 1 (MUC1) T-cells\u003Cbr>Tumor-Associated Macrophages (TAMs) |  |  |  |  |  |\n\nIntroduction  \nDespite advances in screening and treatment of cervical cancer, it remains the fourth most common disease and the leading cause of cancer deaths in women worldwide.1 Adaptive Cell Therapy (ACT) and Immune Checkpoint Inhibitors (ICIs) (such as PD-1/PD-L1) have dramatically prolonged the survival of cervical cancer patients.2 Although anti-PD-1/PD-L1 monoclonal antibodies have achieved outstanding clinical results in the treatment of specific cancer types, their overall response rate is still rather mediocre (12.46 % in US patients in 2018).3 Therefore, the authors need to translate more drug candidates into the  \nclinical arena through more ways and methods to achieve greater success and benefit more patients.  \nSci Transl Med reports that the Sialoglycan/Sialic acid binding Immunoglobulin-like Lectins (SIGLECS) axis is a novel immune checkpoint whose changes greatly influence the stability of the immune system, and that targeting this axis","cbCaikzw9XOFvvRc","https://ap.wps.com/l/cbCaikzw9XOFvvRc","pdf",20112446,18,"English","# Introduction\n## Background and clinical context\n## SIGLECS axis and SIGLEC9 as an immune checkpoint\n## Cellular expression patterns and relevance to immunotherapy","[{\"question\":\"What is the main objective of the study on SIGLEC9?\",\"answer\":\"To investigate how SIGLEC9, an immune checkpoint, contributes to immunosuppression in cervical cancer and how it affects prognosis through interactions with immune cells in the tumor microenvironment.\"},{\"question\":\"How was SIGLEC9 expression and immune infiltration analyzed?\",\"answer\":\"SIGLEC9 expression in cervical cancer was analyzed using the TNM plot, TCGA, and Human Protein Atlas, and its relationship with immune cell infiltration was explored using TCGA and TISIDB.\"},{\"question\":\"What did the study find about SIGLEC9 and prognosis?\",\"answer\":\"SIGLEC9 was significantly upregulated in cervical cancer, and higher expression was associated with poor prognosis, including reduced overall survival linked to elevated SIGLEC9+ tumor-associated macrophages.\"}]","The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer | PDF",1790714879,45]